

Cover Story
PodcastThe Directors
By Sara Willa Ernst and Paul Goldberg
Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).
Podcast
Cancer Policy


In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - In the epicenter of the measles outbreak, “love thy neighbor” does not extend to vaccination rates
A dispatch from Lancaster County




















